Pramlintide has show an influence on the slowing of the gastric emptying time thus reducing the rate of the rise in plasma glucose. Furthermore, four studies in Type I diabetic humans have documented that pramlintide (AC137) therapy reduces post prandial hyperglycemia following a test meal compared to the placebo. This study will be assessing this effect as well as the tolerability of the study drug.
Showing the most recent 10 out of 497 publications